Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Pulmonx Corp. (LUNG) PT Raised to $12 at Citi, Downgraded From Buy-High Risk to Buy
February 23, 2023 5:50 AM ESTCiti analyst Joanne Wuensch raised the price target on Pulmonx Corp. (NASDAQ: LUNG) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Pulmonxs 4Q22 sales were better than expected, delivering $15.4M (up 18.4% y/y ex-fx), ahead of consensuss... More
